248 related articles for article (PubMed ID: 9041192)
1. Prostate cancer progression, metastasis, and gene expression in transgenic mice.
Perez-Stable C; Altman NH; Mehta PP; Deftos LJ; Roos BA
Cancer Res; 1997 Mar; 57(5):900-6. PubMed ID: 9041192
[TBL] [Abstract][Full Text] [Related]
2. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
3. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
4. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model.
Duan W; Gabril MY; Moussa M; Chan FL; Sakai H; Fong G; Xuan JW
Oncogene; 2005 Feb; 24(9):1510-24. PubMed ID: 15674347
[TBL] [Abstract][Full Text] [Related]
5. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice.
Perez-Stable C; Altman NH; Brown J; Harbison M; Cray C; Roos BA
Lab Invest; 1996 Feb; 74(2):363-73. PubMed ID: 8780156
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 accelerates multistep prostate carcinogenesis in vivo.
Bruckheimer EM; Brisbay S; Johnson DJ; Gingrich JR; Greenberg N; McDonnell TJ
Oncogene; 2000 Nov; 19(46):5251-8. PubMed ID: 11077442
[TBL] [Abstract][Full Text] [Related]
7. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
8. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
Shappell SB; Olson SJ; Hannah SE; Manning S; Roberts RL; Masumori N; Jisaka M; Boeglin WE; Vader V; Dave DS; Shook MF; Thomas TZ; Funk CD; Brash AR; Matusik RJ
Cancer Res; 2003 May; 63(9):2256-67. PubMed ID: 12727848
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
11. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
12. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
13. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
14. The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.
Perez-Stable CM; Schwartz GG; Farinas A; Finegold M; Binderup L; Howard GA; Roos BA
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):555-63. PubMed ID: 12050097
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
16. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent.
Asamoto M; Hokaiwado N; Cho YM; Takahashi S; Ikeda Y; Imaida K; Shirai T
Cancer Res; 2001 Jun; 61(12):4693-700. PubMed ID: 11406539
[TBL] [Abstract][Full Text] [Related]
17. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations.
Shibata MA; Ward JM; Devor DE; Liu ML; Green JE
Cancer Res; 1996 Nov; 56(21):4894-903. PubMed ID: 8895741
[TBL] [Abstract][Full Text] [Related]
18. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
[TBL] [Abstract][Full Text] [Related]
19. Progression of prostate cancer from a subset of p63-positive basal epithelial cells in FG/Tag transgenic mice.
Reiner T; de Las Pozas A; Parrondo R; Perez-Stable C
Mol Cancer Res; 2007 Nov; 5(11):1171-9. PubMed ID: 17982114
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]